pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
GIP receptor · news · pharmadog
← back to GIP receptor
News · GIP receptor
52
stories
20h
Despite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbers
biospace
3d
Significant stock movers of September: Viking soars, Longeveron slides
biospace
6d
Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS
biospace
7d
Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again
biospace
8d
Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3
biospace
8d
Lilly builds commercial case for GLP-1 products over Novo with indirect analyses
biospace
8d
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
fiercebiotech
9d
Lilly sets up next-gen obesity battle with full phase 3 retatrutide data
fiercebiotech
9d
Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill
biopharma dive
9d
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
biospace
9d
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
stat
9d
Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal
biospace
9d
Novo to spend $300M upfront to license Hengrui's weekly oral weight loss drug
endpoints
10d
Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui
fiercebiotech
14d
Pioneer of China NewCo model sued in US over trade secret misuse, double-dealing
fiercebiotech
14d
FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’
biospace
14d
Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalry
biospace
15d
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
biospace
16d
Viking shares surge on updated obesity drug data
biopharma dive
16d
Viking achieves 'maintenance trifecta' as GLP-1/GIP dual agonist exceeds expectations
biospace
16d
Lilly presents early data supporting GLP-1/GIP candidate's potential in depression, alcohol use disorder
biospace
16d
Roche’s Carmot asset normalizes blood sugar, cuts weight in Phase 2 diabetes trial
biospace
17d
Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes
fiercebiotech
24d
Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis
fiercebiotech
24d
Lilly cans early experimental obesity drug after ‘high bar’ not met
fiercebiotech
Sep 2, 26
Beyond GLP‑1s: The race for next‑gen obesity drugs starts in the preclinical models
biospace
Aug 28, 26
Lilly joins Novo in cardiovascular space after FDA nod for GLP-1/GIP agonist Mounjaro
biospace
Aug 28, 26
Why Roche is 'really excited' about a UCN2 analog for obesity after seeing preclinical data
fiercebiotech
Aug 27, 26
Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerate
biospace
Aug 24, 26
Roche bets up to $2.3B in Hanmi pact for next-gen weight loss drug
biospace
← prev
page 1 of 2
next →
